Technical Analysis for XRTX - Xortx Therapeutics Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.360 | -2.86% | -0.040 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -2.86% | |
| NR7 | Range Contraction | -2.86% | |
| Narrow Range Bar | Range Contraction | -2.86% | |
| Wide Bands | Range Expansion | -2.86% | |
| Oversold Stochastic | Weakness | -2.86% | |
| New 52 Week Closing Low | Bearish | -2.86% | |
| Volume Surge | Other | -2.86% | |
| Calm After Storm | Range Contraction | -2.86% | |
| Narrow Range Bar | Range Contraction | -2.86% | |
| Lower Bollinger Band Walk | Weakness | -2.86% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 2 hours ago |
| 2x Volume Pace | about 2 hours ago |
| Down 2% | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 1.5x Volume Pace | about 2 hours ago |
Get a Trading Assistant
- Earnings date: 2024-11-12
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Organ Systems Diabetes Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.35 |
| 52 Week Low | 1.28 |
| Average Volume | 3,991 |
| 200-Day Moving Average | 2.720 |
| 50-Day Moving Average | 1.773 |
| 20-Day Moving Average | 1.677 |
| 10-Day Moving Average | 1.672 |
| Average True Range | 0.171 |
| RSI (14) | 35.48 |
| ADX | 16.29 |
| +DI | 33.300 |
| -DI | 26.709 |
| Chandelier Exit (Long, 3 ATRs) | 1.978 |
| Chandelier Exit (Short, 3 ATRs) | 1.792 |
| Upper Bollinger Bands | 2.005 |
| Lower Bollinger Band | 1.349 |
| Percent B (%b) | 0.08 |
| BandWidth | 39.153 |
| MACD Line | -0.079 |
| MACD Signal Line | -0.041 |
| MACD Histogram | -0.0381 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.460 | ||||
| Resistance 3 (R3) | 1.467 | 1.453 | 1.450 | ||
| Resistance 2 (R2) | 1.453 | 1.438 | 1.450 | 1.447 | |
| Resistance 1 (R1) | 1.427 | 1.429 | 1.420 | 1.420 | 1.443 |
| Pivot Point | 1.413 | 1.413 | 1.410 | 1.410 | 1.413 |
| Support 1 (S1) | 1.387 | 1.398 | 1.380 | 1.380 | 1.357 |
| Support 2 (S2) | 1.373 | 1.389 | 1.370 | 1.353 | |
| Support 3 (S3) | 1.347 | 1.373 | 1.350 | ||
| Support 4 (S4) | 1.340 |
